Denali Therapeutics Inc (NASDAQ:DNLI) major shareholder Douglas K. Bratton sold 82,578 shares of Denali Therapeutics stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $24.01, for a total transaction of $1,982,697.78. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
NASDAQ:DNLI opened at $23.70 on Wednesday. The firm has a market capitalization of $2.50 billion, a P/E ratio of -10.77 and a beta of 1.88. The business has a 50 day simple moving average of $25.23 and a 200 day simple moving average of $21.76. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.70 and a quick ratio of 12.70. Denali Therapeutics Inc has a 12-month low of $12.39 and a 12-month high of $30.41.
Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.02. The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $5.93 million. Denali Therapeutics had a negative net margin of 825.96% and a negative return on equity of 46.48%. Research analysts anticipate that Denali Therapeutics Inc will post -2.44 EPS for the current fiscal year.
DNLI has been the topic of a number of recent research reports. Evercore ISI raised Denali Therapeutics from an “in-line” rating to an “outperform” rating and set a $20.00 target price on the stock in a research note on Friday, March 13th. Cantor Fitzgerald reissued a “neutral” rating on shares of Denali Therapeutics in a research note on Wednesday, March 18th. TheStreet raised shares of Denali Therapeutics from a “d+” rating to a “c-” rating in a research report on Wednesday, May 20th. BidaskClub downgraded Denali Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Nomura Securities reiterated a “buy” rating and set a $35.00 price objective on shares of Denali Therapeutics in a research note on Monday, March 9th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $29.91.
Several large investors have recently made changes to their positions in the business. Marshall Wace LLP bought a new position in shares of Denali Therapeutics in the first quarter worth $359,000. Rhumbline Advisers increased its stake in Denali Therapeutics by 1.2% during the 4th quarter. Rhumbline Advisers now owns 63,512 shares of the company’s stock valued at $1,106,000 after buying an additional 782 shares during the period. Swiss National Bank raised its position in shares of Denali Therapeutics by 2.6% during the 4th quarter. Swiss National Bank now owns 119,300 shares of the company’s stock worth $2,078,000 after buying an additional 3,000 shares in the last quarter. State Street Corp lifted its stake in shares of Denali Therapeutics by 0.6% in the 4th quarter. State Street Corp now owns 1,602,182 shares of the company’s stock worth $27,910,000 after acquiring an additional 10,089 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Denali Therapeutics by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 374,478 shares of the company’s stock valued at $6,524,000 after acquiring an additional 7,203 shares in the last quarter. Institutional investors own 75.03% of the company’s stock.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Recommended Story: How prevalent are 12b-1 fees?
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.